Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the narcolepsy drugs market size evolved in recent years?

The market size for drugs treating narcolepsy has experienced substantial growth in the past few years. The market is projected to expand from a value of $3.62 billion in 2024 to $3.97 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.9%. The remarkable growth during the historic period is due to several factors including heightened awareness and diagnosis, better treatment alternatives, regulatory approvals, rising awareness and diagnosis rates, and the broadening scope of healthcare services.

What are the predictions for the narcolepsy drugs market size in the coming years?

In the coming years, strong expansion is anticipated in the narcolepsy drugs market, which is projected to reach $5.73 billion in 2029, growing at a compound annual growth rate (CAGR) of 9.6%. The expected rise during the projection period can be ascribed to an increase in sleep disorder cases, strides in customized medicine, an aging community more susceptible to sleep disorders, escalation of improved patient support and aid programs, and widespread healthcare insurance. The forecast period is likely to see significant trends like breakthroughs in technology, pharmaceutical companies maintaining their focus on patients, progress in biologic therapy research, groundbreaking drug formulations, and a pivot towards non-stimulant options.

Get your narcolepsy drugs market report here!

https://www.thebusinessresearchcompany.com/report/narcolepsy-drugs-global-market-report

What key factors are fueling the growth of the narcolepsy drugs market?

The increase in need for personalized healthcare is projected to fuel the expansion of the narcolepsy drugs market. Personalized healthcare is a medical philosophy that advocates for the customization of treatments and interventions according to each patient’s unique needs. The surge in demand for such tailored medicines can be attributed to the fast-paced advancement of omics technology, data amalgamation, genetics, and the understanding of the importance of personalised medicines and preventive measures tailored to individual patients. Narcolepsy drugs come into play in this personalized approach by being part of the treatment plan designed considering a patient’s genetic makeup, severity of symptoms, metabolic rates, and individual preferences. This helps maximize the effectiveness of these drugs and reduce potential side effects. As reported by the Personalized Medicine Coalition, a professional organization based in the United States, around 12 new tailored medications received approval in 2022, making up about 34% of all newly approved treatments for that year, representing a growth compared to 2021. Thus, the increasing need for customized medication bolsters the growth of the narcolepsy drugs market.

How is the global narcolepsy drugs market divided into key segments?

The narcolepsy drugs market covered in this report is segmented –

1) By Type: Narcolepsy With Cataplexy, Narcolepsy Without Cataplexy, Secondary Narcolepsy

2) By Disease: Daytime Extreme Sleepiness, Cataplexia, Other Diseases

3) By Therapeutic: Sodium Oxybate, Central Nervous System Stimulants, Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitor, Other Therapeutics

Subsegments:

1) By Narcolepsy With Cataplexy: Stimulant Medications, Antidepressants, Sodium Oxybate

2) By Narcolepsy Without Cataplexy: Stimulant Medications, Sodium Oxybate, Selective Serotonin And Norepinephrine Reuptake Inhibitors (SNRIs)

3) By Secondary Narcolepsy: Treatment For Underlying Conditions, Stimulants And Other Medications For Symptom Management

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16490&type=smp

Who are the key firms paving the way for growth in the narcolepsy drugs market?

Major companies operating in the narcolepsy drugs market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB SA, Sun Pharmaceutical Industries Ltd., Jazz Pharmaceutical plc, Ipsen Group, Lundbeck AS, Hikma Pharmaceuticals plc, Lupin Limited, Viatris Inc., Harmony Biosciences Holdings Inc., Ligand Pharmaceuticals Incorporated, Sumitomo Dainippon Pharma Co. Ltd., Avadel Pharmaceuticals plc, Bioprojet Pharma s.a.r.l, Graymark Healthcare Inc., Flamel Technologies SA, Arena Pharmaceuticals

What key trends are currently impacting the narcolepsy drugs market’s development?

In the narcolepsy drugs market, prominent companies are pursuing the development of novel products, such as extended-release treatments, to improve both the effectiveness of treatment and the patient’s experience. Patients with narcolepsy reap considerable advantages from extended-release (ER) treatments as they aid in improved medication adherence, stabilization of drug levels, minimized side effects, and enhanced handling of symptoms. For example, in May 2023, Avadel Pharmaceuticals, a corporation specializing in pharmaceuticals based in Ireland, introduced Lumryz, an extended-released sodium oxybate drug sanctioned by the Food and Drug Administration (FDA), a federal agency based in the United States. Lumryz comes with an innovative extended-release mechanism that permits patients to sustain stable therapeutic levels throughout the night with just one dose, offering greater convenience and adherence than the conventional multiple-dose regimes. This novel drug meets a crucial unmet need by simplifying treatment schedules, which in turn could improve patient adherence and overall life quality for those dealing with narcolepsy.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16490

What regions are contributing significantly to the growth of the narcolepsy drugs market?

North America was the largest region in the narcolepsy drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the narcolepsy drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Breast Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Bladder Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bladder-cancer-drugs-global-market-report

Narcotics Scanner Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/narcotics-scanner-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: